Dechra Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 1/6
Dechra Pharmaceuticals possède un total de capitaux propres de £755.2M et une dette totale de £487.6M, ce qui porte son ratio d'endettement à 64.6%. Son actif total et son passif total sont £1.6B et de £814.2M. L'EBIT de Dechra Pharmaceuticals est £17.1M ce qui fait que son ratio de couverture des intérêts 0.8. Elle dispose de liquidités et de placements à court terme de £74.4M.
Informations clés
64.6%
Ratio d'endettement
UK£487.60m
Dette
| Ratio de couverture des intérêts | 0.8x |
| Argent liquide | UK£74.40m |
| Fonds propres | UK£755.20m |
| Total du passif | UK£814.20m |
| Total des actifs | UK£1.57b |
Mises à jour récentes de la santé financière
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31
We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04Recent updates
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Mar 28We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125
Mar 02Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Dec 09Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289
Oct 06Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year
Sep 22Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289
Sep 08Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Aug 18Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?
Aug 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
May 08Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?
Apr 22Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12
Feb 23Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 29Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?
Jan 11Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
Oct 15Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Sep 25Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29
Sep 11With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting
Sep 08Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?
Jun 17Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?
Apr 09Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet
Mar 05Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17
Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Feb 02Analyse de la situation financière
Passif à court terme: Les actifs à court terme de DPH ( £467.9M ) dépassent ses passifs à court terme ( £164.0M ).
Passif à long terme: Les actifs à court terme de DPH ( £467.9M ) ne couvrent pas ses passifs à long terme ( £650.2M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de DPH ( 54.7% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de DPH est passé de 57.6% à 64.6% au cours des 5 dernières années.
Couverture de la dette: La dette de DPH n'est pas bien couverte par le flux de trésorerie opérationnel ( 13% ).
Couverture des intérêts: Les paiements d'intérêts de DPH sur sa dette ne sont pas bien couverts par l'EBIT ( 0.8 x couverture).